[1]汤建林,李玉莹,高柳艳,等.131I治疗Graves病规范化建设体会[J].国际放射医学核医学杂志,2011,35(3):179-180,193.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]
　TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.Standardization of 131I therapy for Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):179-180,193.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]
点击复制

131I治疗Graves病规范化建设体会(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第3期
页码:
179-180,193
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Standardization of 131I therapy for Graves disease
作者:
汤建林;  李玉莹;  高柳艳;  唐秀萍;  胡红永
大理白族自治州人民医院核医学科, 云南大理 671000
Author(s):
TANG Jian-lin;  LI Yu-ying;  GAO Liu-yan;  TANG X iu-ping;  HU Hong-yong
Department of Nuclear Medicine, The People’s Hospital of the Dali Autonomous Prefcture, Yunnan Dali 671000, China
关键词:
格雷夫斯病; 碘放射性同位素; 放射疗法; 规范
Keywords:
Graves disease; Iodine radioisotopes; Radiotherapy; Benchmarking
DOI:
10.3760/cma.j.issn.1673-4114.2011.03.011
摘要:
目的 建立131I治疗Graves病规范化措施,保障医疗安全和医疗质量。方法 制定131I治疗Graves病的组织措施和技术措施,对Graves病患者进行131I规范化治疗并定期随访。结果 接受131I治疗的104例患者,随访6~36月,均无不良反应发生,一次治愈率为59.6%,有效率为99.9%,疗效满意。结论 131I治疗Graves病规范化建设是医疗质量和医疗安全的重要保证。
Abstract:
Objective To establish the normative and standard measures,to ensure medical safety and quality of care of the patients with Graves disease treated by 131I therapy.Methods Formulating and strictly implementing the medical organizational and technical measures of 131I therapy for Graves disease and regular follow-up.Results Receiving 131I treatment of 104 patients,follow-up 6-36 months,no adverse events,the cure rate of 59.6%,the efficient rate is 99.9%.Conclusion It is important guarantee for the medical quality and safety to standardize the 131I therapy of Graves disease.

参考文献/References:

[1] 陆再英,钟南山.内科学.7版.北京:人民卫生出版社,2008:712-721.
[2] 邢家骝.131I治疗甲状腺功能亢进症.北京:人民卫生出版社,2002:152.
[3] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症.中华内科杂志.2007,10(46):876-882.
[4] Brent GA.Graves’ disease.N Engl J Med,2008,358(24):2594-2605
[5] 中华医学会核医学分会.甲状腺疾病的131I治疗.中华医学会.临床技术操作规范·核医学分册.北京:人民军医出版社,2004.175-177.
[6] 匡安仁.内分泌疾病的治疗//张永学.核医学.北京:人民卫生出版社,2005:353-358.
[7] 汤建林,李玉莹,高柳艳,等.甲状腺功能亢进症治疗方法的比较和选择[J].国际放射医学核医学杂志,2009,33(3):175-178.

相似文献/References:

[1]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[4]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[8]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
　Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b（Pseudomonas putida）administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
[9]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[10]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[15]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[16]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[17]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[18]牟联超,李先映,石彩虹.131I治疗青少年Graves病58例临床分析[J].国际放射医学核医学杂志,2010,34(5):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
　MU Lian-chao,LI Xian-ying,SHI Cai-hong.Analyze of 131I therapy on 58 youngsters with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
[19]查金顺,黄春玲,蒋婷吟,等.131I治疗Graves甲状腺功能亢进症中碳酸锂的应用[J].国际放射医学核医学杂志,2011,35(2):93.[doi:10.3760/cma.j.issn.1673-4114.2011.02.007]
　ZHA Jin-shun,HUANG Chun-ling,JIANG Ting-yin,et al.Application of lithium carbonate on radioiodine treatment of Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):93.[doi:10.3760/cma.j.issn.1673-4114.2011.02.007]
[20]钟兴祥,郑吉祥,蓝冠章,等.Graves甲亢131I治疗前后血清TRAb动态变化及临床价值[J].国际放射医学核医学杂志,2011,35(2):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
　ZHONG Xing-xiang,ZHENG Ji-xiang,LAN Guan-zhang,et al.Changes of serum TRAb after 131I radiotherapy in patients of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]

备注/Memo

备注/Memo:
收稿日期:2011-01-08。
通讯作者:汤建林(Email:tjl128@163.com)
更新日期/Last Update: 1900-01-01